Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2005 1
2006 1
2007 1
2009 1
2010 1
2011 3
2012 1
2013 1
2014 1
2015 1
2016 5
2017 2
2018 7
2019 6
2020 7
2021 8
2022 14
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, Shameem SH, Chauhan T, Torrisi J, Ford J, O'Connor MN, Geuijen CAW, Schackmann RCJ, Lammerts van Bueren JJ, Wasserman E, de Stanchina E, O'Reilly EM, Ladanyi M, Drilon A, Somwar R. Schram AM, et al. Among authors: somwar r. Cancer Discov. 2022 May 2;12(5):1233-1247. doi: 10.1158/2159-8290.CD-21-1119. Cancer Discov. 2022. PMID: 35135829 Free PMC article.
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.
Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, Chang JC, Paik PK, Offin M, Arcila ME, Davare MA, Shinde U, Pe'er D, Rekhtman N, Kris MG, Somwar R, Riely GJ, Ladanyi M, Yu HA. Schoenfeld AJ, et al. Among authors: somwar r. Clin Cancer Res. 2020 Jun 1;26(11):2654-2663. doi: 10.1158/1078-0432.CCR-19-3563. Epub 2020 Jan 7. Clin Cancer Res. 2020. PMID: 31911548 Free PMC article.
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy.
Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Kuwahara Y, Somwar R, Ladanyi M, Qu R, De Stanchina E, Dela Cruz FS, Kung AL, Gounder M, Kentsis A. Kazansky Y, et al. Among authors: somwar r. bioRxiv [Preprint]. 2023 Dec 1:2023.02.06.527192. doi: 10.1101/2023.02.06.527192. bioRxiv. 2023. PMID: 36798379 Free PMC article. Updated. Preprint.
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I, Makarem M, Nishino M, Bachert SE, Zhang T, LoPiccolo J, Paweletz CP, Gokhale PC, Ivanova E, Saldanha A, Rudin CM, Lockwood WW, Ladanyi M, Somwar R, Jänne PA, Sholl LM. Odintsov I, et al. Among authors: somwar r. J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428-0. doi: 10.1016/j.jtho.2023.12.019. Online ahead of print. J Thorac Oncol. 2023. PMID: 38154514
A blast from the past: ROS1 on the brain.
Odintsov I, Somwar R, Davare MA. Odintsov I, et al. Among authors: somwar r. Oncotarget. 2019 Mar 1;10(18):1664-1666. doi: 10.18632/oncotarget.26752. eCollection 2019 Mar 1. Oncotarget. 2019. PMID: 30899438 Free PMC article. No abstract available.
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield SE, Bhanot U, Vanderbilt CM, Cheng EH, Drilon A, Riely GJ, Lockwood WW, de Stanchina E, Tirunagaru VG, Doebele RC, Quintanal-Villalonga Á, Rudin CM, Somwar R, Ladanyi M. Elkrief A, et al. Among authors: somwar r. J Thorac Oncol. 2023 Sep;18(9):1165-1183. doi: 10.1016/j.jtho.2023.05.007. Epub 2023 May 13. J Thorac Oncol. 2023. PMID: 37182602
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, Rodriguez FJ, Gross JM, Allen AN, Wan X, Somwar R, Schreck KC, Kessler L, Wang J, Pratilas CA. Odeniyide P, et al. Among authors: somwar r. Oncogene. 2022 May;41(21):2973-2983. doi: 10.1038/s41388-022-02305-x. Epub 2022 Apr 22. Oncogene. 2022. PMID: 35459782 Free PMC article.
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H, Nilsson MB, Robichaux JP, He J, Poteete A, Jiang H, Heeke S, Elamin YY, Shibata Y, Matsumoto S, Yoh K, Okazaki S, Masuko T, Odintsov I, Somwar R, Ladanyi M, Goto K, Heymach JV. Udagawa H, et al. Among authors: somwar r. J Thorac Oncol. 2024 Jan;19(1):106-118. doi: 10.1016/j.jtho.2023.08.034. Epub 2023 Sep 9. J Thorac Oncol. 2024. PMID: 37678511
64 results